Huong T. Pham
Expertise in
28
conditions

Dr. Huong T. Pham

Radiation Oncology
1100 Ninth Avenue, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
28
conditions
1100 Ninth Avenue, 
Seattle, WA 

Overview

Huong Pham, MD, is a board-certified radiation oncologist with special interest in brain tumors, radiosurgery, breast cancer, prostate cancer and brachytherapy.Dr. Pham strives to be accessible to her patients, welcoming their questions and concerns. In collaboration with her multidisciplinary team, she does everything in her power to give her patients the highest quality, safest and most accurate treatment available.Away from work, Dr. Pham enjoys spending time with her family and playing sports including tennis, snowboarding and surfing.

Dr. Pham is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Radiation Induced Meningioma, Meningioma, Familial Prostate Cancer, and Posterior Fossa Tumor.

Dr. Pham is board certified in American Board Of Radiology, Subspecialty In Radiation Oncology. She is actively involved in clinical research, co-authoring 18 peer reviewed articles and participating in 13 clinical trials. Dr. Pham is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in WA

Board Certifications

American Board Of Radiology, Subspecialty In Radiation Oncology

Fellowships

Radiation Oncology - Central Nervous System Tumors - 1997

Hospital Affiliations

Highline Medical Center
Virginia Mason Medical Center
St Francis Community Hospital
Virginia Mason Medical Center.
Puget Sound High Value Network.
Rainier Health Network.

Languages Spoken

English
Spanish
Vietnamese

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Virginia Mason Medical Center
1100 Ninth Avenue, Seattle, WA 98101

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Procedure, Other
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2026
Intervention Type: Radiation, Drug
Study Phase: Phase 3
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Completed
Publish Date: April 22, 2026
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2026
Intervention Type: Procedure, Other
View 9 Less Clinical Trials

18 Total Publications

Norlichexanthone, a shunt product of Griseofulvin, disrupts spindle assembly checkpoint and nucleocytoplasmic transport by targeting TPR in the nuclear pore complex.
Norlichexanthone, a shunt product of Griseofulvin, disrupts spindle assembly checkpoint and nucleocytoplasmic transport by targeting TPR in the nuclear pore complex.
Journal: Bioorganic chemistry
Published: March 05, 2026
Similar Doctors
Expertise in
29
conditions
Dr. Lia M. Halasz
Radiation Oncology
Expertise in
29
conditions
Dr. Lia M. Halasz
Radiation Oncology
Referral may be required

Summit Cardiology Trust

1560 N 115th St, 
Seattle, WA 
 (7.2 miles away)
Languages Spoken:
English, German, Korean, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Lia Halasz is a Radiation Oncologist practicing medicine in Seattle, Washington. Dr. Halasz is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Oligodendroglioma, Astrocytoma, Brain Tumor, and Glioblastoma. Dr. Halasz is currently accepting new patients.

Expertise in
21
conditions
Dr. Simon S. Lo
Radiation Oncology
Expertise in
21
conditions
Dr. Simon S. Lo
Radiation Oncology
Referral may be required

Gme Office University Of Washington

1959 NE Pacific St, 
Seattle, WA 
 (2.9 miles away)
206-598-4100
Languages Spoken:
English, Cantonese, Hindi, Kannada, Mandarin, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Simon Lo is a Radiation Oncologist practicing medicine in Seattle, Washington. Dr. Lo is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, Pancreaticoduodenectomy, and Endoscopy. Dr. Lo is currently accepting new patients.

Expertise in
18
conditions
Dr. Yolanda D. Tseng
Radiation Oncology
Expertise in
18
conditions
Dr. Yolanda D. Tseng
Radiation Oncology
Referral may be required

Seattle Proton Center LLC

1570 N 115th St, 
Seattle, WA 
 (7.1 miles away)
206-306-2800
Experience:
17+ years
Languages Spoken:
English, Filipino, French, Mandarin, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Yolanda Tseng is a Radiation Oncologist practicing medicine in Seattle, Washington. She has been practicing medicine for over 17 years. Dr. Tseng is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Merkel Cell Carcinoma, Embryonal Tumor with Multilayered Rosettes, Glioblastoma, and Gliosarcoma. Dr. Tseng is currently accepting new patients.

Frequently Asked Questions about Dr. Huong T. Pham

How do I make an appointment with Dr. Huong T. Pham?

You can book an appointment with Dr. Huong T. Pham by calling their office at 206-223-6801. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Huong T. Pham a top-rated expert for Radiation Induced Meningioma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Huong T. Pham is classified as an Distinguished expert for Radiation Induced Meningioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Huong T. Pham specialize in?

While Dr. Huong T. Pham is a Radiation Oncology, they have specific expertise in Radiation Induced Meningioma, Meningioma, and Familial Prostate Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Huong T. Pham participate in research or clinical trials?

Yes. Dr. Huong T. Pham has published 18 articles and abstracts on conditions like Radiation Induced Meningioma. You can view a list of Dr. Huong T. Pham's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Huong T. Pham accept my insurance?

Dr. Huong T. Pham accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 206-223-6801 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pham's expertise for a condition
ConditionClose
    View All 24 Advanced Conditions
    View All 58 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile